The Diagnostic Value of the Correlation between Serum Anti-p53 Antibody and Positron Emission Tomography Parameters in Lung Cancer

Abstract

Objective:Mutations in the p53 gene are the most commonly observed genetic abnormalities in malignancies. The purpose of this study was to assess the diagnostic value of serum anti-p53 antibody (Ab) along with the correlation between serum anti-p53 Ab level and quantitative positron emission tomography (PET) parameters such as maximum standardized uptake value (SUVmax), SUVave, metabolic tumor volume, total lesion glycolysis (TLG) and tumor size.Methods:Serum anti-p53 Ab level was studied in three groups. Patients who underwent 18F-fluorodeoxyglucose (FDG) PET/computed tomography (CT) imaging for staging of previously diagnosed lung cancer constituted the first group, while patients who underwent 18F-FDG PET/CT imaging for evaluation of suspicious pulmonary nodules detected on thorax CT and did not show pathologic FDG accumulation (NAPN=pulmonary nodule with non avid-FDG) were enrolled in the second group. The third group consisted of healthy volunteers.Results:Twenty-eight patients with lung cancer (median age: 62.5, range: 39-77years), 28 patients with NAPN (median age: 65, range: 33-79 years), and 24 healthy volunteers (median age: 62, range: 44-74 years) were enrolled in the study. The serum anti-p53 Ab level was low in healthy volunteers while it was higher in both lung cancer patients and NAPN patients (p<0.05). When serum anti-p53 Ab level and PET parameters were evaluated, there was no significant correlation between serum anti-p53 Ab level and SUVmax, SUVave, TLG, tumor volume and tumor size of patients with lung cancer (p>0.05). Besides, there was no significant difference between serum anti-p53 Ab level and lesion size of NAPN patients (p>0.05).Conclusion:It was determined that serum anti-p53 Ab levels are not significantly correlated with PET parameters, and that serum anti-p53 Ab levels increase in any benign or malignant lung parenchyma pathology as compared to healthy volunteers. These results indicate that this Ab cannot be used as a predictor of malignancy in a lung lesion.

Toll-like receptor expression in human non-small cell lung carcinoma: potential prognostic indicators of disease

“…More studies are needed to further investigate the addition of these markers into gene panels in current use for early detection and predictive models as well as additional studies in serum of patients similar to the soluble TLR4 study recently published. For example, a combination of identifying TLRs in serum and 18F-FDG positron emission tomography (PET) imaging could aid in determining what patients are sensitive to TLR therapies, similar to other markers (eg p53,[ 64 ]). The future of TLRs and their role and possible utility in cancer research will rely on a better understanding of the role of these individual TLRs and the combination of TLRs in the tumor microenvironment, tumor development, and progression, including the specific dimer partners for some TLRs, different types and subtypes of cancer (i.e.…”

RETRACTED ARTICLE: Research on the coordinated development of environmental protection and industry in poverty alleviation under uncertainty

“…Therefore, the local government and enterprises entering the field of poverty alleviation are the main parts of pursuing the optimal allocation of resources. They also need to fulfil their environmental responsibilities and bear the penalties and aftercare costs caused by environmental pollution (Hasbek et al, 2016;Scheidel, 2013;Resnick & Birner, 2006). There are a series of contradictions and conflicts in the process of decision-making between enterprises and local governments (Pal & Saha, 2015;Xing et al, 2019).…”

The Diagnostic Contribution of (18)F-FDG PET/CT Scan in Cancer of Unknown Primary

“…F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography combined with computed tomography (PET/CT) is a non-invasive diagnostic nuclear medicine imaging method which the existence of a proven tumor metastasis without evidence of a primary origin, and the management of the patients with CUP 5 . 18 F-FDG PET/CT is allowing to determinate the localization of increased metabolic activity in tumor tissue 6 . Also there are several research results about the performance of 18 F-FDG PET/CT in patients with CUP in the literature.…”